uniQure Advances Huntington’s Therapy Toward FDA Submission Amid Strong Financial Position
Event summary
- uniQure plans to submit a Biologics License Application (BLA) for AMT-130 in Q3 2026, following alignment with the FDA on accelerated approval pathway.
- Four-year data from Phase I/II studies of AMT-130 expected in September 2026.
- AMT-260 for refractory mesial temporal lobe epilepsy shows early biological signals and favorable safety profile.
- $259 million follow-on offering extends cash runway into 2030, funding pipeline investment.
The big picture
uniQure’s strategic focus on Huntington’s disease therapy (AMT-130) positions it at the forefront of gene therapy innovation, with regulatory submissions on track. The company’s strong financial position, bolstered by a $259 million offering, underscores its ability to fund pipeline advancements amid competitive biotech landscape dynamics.
What we're watching
- Regulatory Alignment
- Whether the FDA’s alignment on confirmatory study design will expedite AMT-130 approval and commercial launch.
- Clinical Progress
- The pace at which AMT-260 advances through Phase I/IIa trials, given early biological signals.
- Financial Execution
- How uniQure allocates its $810.3 million cash position to support pipeline and potential commercialization of AMT-130.
Related topics